Highlights of This Issue 1345

SPECIAL FEATURES

Editors’ Note

1347  Introducing New Strategies in…
James L. Abbruzzese, Alexander M.M. Eggermont, and Eric H. Rubin

CCR New Strategies

1348  New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance
Brian I. Rini

CCR Translations

1355  Does Lapatinib Work against HER2-negative Breast Cancers?
Ingrid A. Mayer and Carlos L. Arteaga
See article p. 1486

Statistics in Clinical Cancer Research

1358  Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge
Irina Ostrovnaya and Colin B. Begg

CCR Drug Updates

1368  Everolimus
Peter J. Houghton

Molecular Pathways

1373  HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Marcia R. Campbell, Dhara Amin, and Mark M. Moasser

1384  Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward
David G. Menter, Richard L. Schilsky, and Raymond N. DuBois

HUMAN CANCER BIOLOGY

1391  High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel Adenocarcinomas
Begoña Diosdado, Tineke E. Buffart, Russell Watkins, Beatriz Carvalho, Bauke Ylstra, Marianne Tijssen, Anne S. Bolijn, Fraser Lewis, Karen Maude, Caroline Verbeke, Iris D. Nagtegaal, Heike Grabsch, Chris J.J. Mulder, Phil Quirke, Peter Howdle, and Gerrit A. Meijer

1402  Critical Role of Ge12 and Ge13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo
Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, and Achim Aigner

1416  Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal Cancer
Xiaoxiang Guan, Erich M. Sturgis, Dapeng Lei, Zhensheng Liu, Kristina R. Dahlstrom, Qingyi Wei, and Guojun Li

1423  ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB
Yuqing Zhang, Uddalak Bharadwaj, Craig D. Logsdon, Changyi Chen, Qizhi Yao, and Min Li

1431  Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2
Jürgen Becker, Helena Pavlakovic, Fabian Ludewig, Fabiola Wilting, Herbert A. Weich, Romulo Albuquerque, Jayakrishna Ambati, and Jörg Wilting
CANCER THERAPY: PRECLINICAL

Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy

1442 Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer

1452 Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann

An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity

1466 Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Pepelski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay

Lestaurnitib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma

1478 Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance


Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation

1498 Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

1509 Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

1520 Katleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Eggert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavrinov, John M. Maris, Jaume Mora, Akira Nakagawara, André Oberthuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele

Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers


Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

1542 Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fish, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, and Thorsten Schlomm

IMAGING, DIAGNOSIS, PROGNOSIS

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

1554 Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fish, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, and Thorsten Schlomm

Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

Katleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Eggert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavrinov, John M. Maris, Jaume Mora, Akira Nakagawara, André Oberthuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele

Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers


Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fish, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, and Thorsten Schlomm
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1587</td>
<td>Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab</td>
<td>Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi</td>
</tr>
<tr>
<td>1597</td>
<td>IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report for Research and Treatment of Cancer Brain Tumor Group</td>
<td>Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorns, Pieter Wesseling, Marc Frenay, Coes C. Tijsen, Denis Lacombe, Ahmed Idhailb, Ronald van Marion, Johan M. Kros, Winand N.M. Djinens, Thierry Gorlia, and Marc Sanson</td>
</tr>
<tr>
<td>1605</td>
<td>Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERIASAC Randomized Placebo-Controlled Trial</td>
<td>Nigel J. Bundred, Angela Cramer, Julie Morris, Lorna Renshaw, Kwok-Leung Cheung, Pamela Flint, Rachael Johnson, Oliver Young, Göran Landberg, Sue Grassby, Lorraine Turner, Andrew Baildam, Lester Barr, and J. Michael Dixon</td>
</tr>
<tr>
<td>1624</td>
<td>Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer</td>
<td>Josefine Becker, Lambert Skoog, Tommy Fonfandier, Bo Nordenskjöld, and Olle Stål</td>
</tr>
<tr>
<td>1634</td>
<td>A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 704028), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma</td>
<td>Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo</td>
</tr>
<tr>
<td>1642</td>
<td>Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes</td>
<td>Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz</td>
</tr>
</tbody>
</table>
The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.